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Abstract
Background: The oncogene CDC25B phosphatase plays an important role in cancer cell growth. We have recently
reported that patients with esophageal squamous cell carcinoma (ESCC) have significantly higher serum levels of
CDC25B autoantibodies (CDC25B-Abs) than both healthy individuals and patients with other types of cancer;
however, the potential diagnostic or prognostic significance of CDC25B-Abs is not clear. The aim of this study is to
evaluate the clinical significance of serum CDC25B-Abs in patients with ESCC.
Methods: CDC25B autoantibodies were measured in sera from both 134 patients with primary ESCC and 134
healthy controls using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which anti-CDC25B
antibodies bound CDC25B antigen purified from Eca-109 ESCC tumor cells. The clinicopathologic significance of
CDC25B serum autoantibodies was compared to that of the tumor markers carcinoembryonic antigen (CEA),
squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragment antigen 21-1(CYFRA21-1).
Results: Higher levels of CDC25B autoantibodies were present in sera from patients with ESCC (A450 = 0.917, SD =
0.473) than in sera from healthy control subjects (A450 = 0.378, SD = 0.262, P < 0.001). The area under the receiver
operating characteristic (ROC) curve for CDC25B-Abs was 0.870 (95% CI: 0.835-0.920). The sensitivity and specificity
of CDC25B-Abs for detection of ESCC were 56.7% and 91.0%, respectively, when CDC25-Abs-positive samples were
defined as those with an A450 greater than the cut-off value of 0.725. Relatively few patients tested positive for the
tumor markers CEA, SCC-Ag and CYFRA21-1 (13.4%, 17.2%, and 32.1%, respectively). A significantly higher number
of patients with ESCC tested positive for a combination of CEA, SCC, CYFRA21-1 and CDC25B-Abs (64.2%) than for
a combination of CEA, SCC-Ag and CYFRA21-1 (41.0%, P < 0.001). The concentration of CDC25B autoantibodies in
serum was significantly correlated with tumor stage (P < 0.001). Although examination of the total patient pool
showed no obvious relationship between CDC25B autoantibodies and overall survival, in the subgroup of patients
with stage III-IV tumors, the cumulative five-year survival rate of CDC25B-seropositive patients was 6.7%, while that
of CDC25B-seronegative patients was 43.4% (P = 0.001, log-rank). In the N1 subgroup, the cumulative five-year
survival rate of CDC25B-seropositive patients was 13.6%, while that of CDC25B-seronegative patients was 54.5%
(P = 0.040, log-rank).
Conclusions: Detection of serum CDC25B-Abs is superior to detection of the tumor markers CEA, SCC-Ag and
CYFRA21-1 for diagnosis of ESCC, and CDC25B-Abs are a potential prognostic serological marker for advanced
ESCC.
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Esophageal squamous cell carcinoma (ESCC), the major
histopathological form of esophageal cancer, is one of
the most lethal malignancies of the digestive tract and is
the fourth most frequent cause of cancer deaths in
China [1]. Despite the improvements in surgical techni-
ques and adjuvant chemoradiation for patients with
ESCC, the five-year survival rate of patients with
advanced ESCC is still poor [2]. This poor survival rate
is largely due to the lack of serological markers for early
diagnosis and prediction of disease progression; patients
are frequently diagnosed with ESCC when they have
already reached an advanced stage of disease [3]. There
is thus a growing need to identify useful biological mar-
kers for early, non-invasive diagnosis of ESCC and for
monitoring tumor progression [4].
In addition to the traditional tumor markers CEA,
SCCA and CYFRA21-1, autoantibodies against tumor-
associated antigens were recently reported in sera from
patients with ESCC. Similar to the traditional tumor
markers, these autoantibodies were shown to be useful
molecular markers for ESCC. Some patients with ESCC
mount an immunological reaction against several
tumor-associated antigens, including p53 [5-7], myome-
galin [8] and TRIM21 [9]. Recently, a proteomics-based
approach identified several autoantibodies in sera of
patients with ESCC, such as anti-heat shock protein 70
[10] and anti-peroxiredoxin VI [11]. The presence of
these autoantibodies in sera has been reported as a use-
ful marker for early diagnosis or for prediction of dis-
ease progression in patients with ESCC.
Most recently, we identified CDC25B autoantibodies
in sera from patients with ESCC using a proteomics-
based technique[12]. Three CDC25B phosphatases exist
in higher eukaryotes, CDC25A, CDC25B and CDC25C
[13]. CDC25B has been shown to play an important role
in tumorigenesis [14]. First, CDC25B can transform
fibroblast cells lacking functional retinoblastoma protein
or harboring mutated Ras protein[15]. Second, CDC25B
activates the mitotic kinase CDK1/cyclin B complex in
the cytoplasm to stimulate cell cycle progression [16].
Furthermore, overexpression of CDC25B has been
observed in a variety of human cancers, including colon
cancer[17], medullary thyroid carcinoma [18], breast
cancer [19], non-Hodgkin’s lymphomas[20], non-small
cell lung cancer [21] and ESCC[22-25]. We previously
reported that aberrant expression of CDC25B in ESCC
tumor cells can induce CDC25B autoantibodies in sera
of ESCC patients, and antibodies against CDC25B were
detected in sera of 36.3% of patients with ESCC, but not
in sera of healthy controls, by reverse capture ELISA
[12]. Our findings suggest that CDC25B autoantibodies
are a novel serum marker for ESCC.
Although higher levels of anti-CDC25B antibodies
were found in the sera of patients with ESCC than in
t h es e r ao fh e a l t h yc o n t r o l s , the relationship between
tumor burden, tumor staging and antibody levels
remains unknown. In addition, the potential utility of
anti-CDC25B antibodies for diagnosis of ESCC has not
been clearly addressed. In this study, we established a
reverse capture ELISA to detect anti-CDC25B antibodies
in sera from patients with ESCC and evaluated the clini-
cal values of CDC25B autoantibodies for diagnosis of
ESCC and prediction of tumor progression.
Methods
Patients and sera
Sera were collected from 134 patients with primary
ESCC at the time of diagnosis before tumor resection at
the Cancer Center of Sun Yat-sen University between
January 2003 and December 2004. Ninety-three patients
were male and 41 patients were female. The patients
ranged in age from 38 to 81 years (mean, 58.5 years),
and none of them had received radiation therapy or che-
motherapy before surgery. Sera from 134 healthy volun-
t e e r s( 9 1m a l e sa n d4 3f e m a l e sw i t ha g e sr a n g i n gf r o m
40 to 70 years (mean, 61 years)) were collected and used
as controls. Prior to the use of these sera, informed con-
sent was obtained from patients and experiments were
approved by the Institute Research Ethics Committee.
After collection, sera were immediately aliquoted and
stored at -80°C until use.
Cell lines
The ESCC cell lines Eca-109, TE-1, and Kyse140 (Cell
Bank of Type Culture Collection of Chinese Academy of
Sciences, Shanghai, China) were grown in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum, 100 μg/L streptomycin, and 100 μg/L
penicillin in a humidified incubator containing 5% CO2
at 37°C. The immortalized esophageal cell line NE-3
was obtained from Dr. Jin (the University of Hong
Kong, P. R. China)[26] and cultured in Keratinocyte-
SFM (Invitrogen, Carlsbad, CA).
Western blot analysis
Western blots were performed as described previously
[27]. The membranes were stained with a 1:1000 dilu-
tion of an anti-CDC25B antibody (Cell Signaling Tech-
nology, Danvers, MA) or with a 1:2000 dilution of a
mouse monoclonal anti-a-tubulin antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). A non-tumorous tissue
protein was obtained from a patient with ESCC who
underwent surgical esophageal tissue resection at the
Cancer Center of Sun Yat-sen University (Guangzhou,
P. R. China) during 2009 and used as a negative control.
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Antigen protein was extracted from the ESCC cell lines
and prepared as reported previously [28]. Briefly, after
washing the cells three times with phosphate-buffered
saline (PBS), the cells were collected and incubated at a
concentration of 10
7 cells/ml in a lysis buffer composed
of Tris base (10 mmol/L), NaCl (150 mmol/L), Triton-X
(0.1%) and a proteinase inhibitor cocktail, placed on ice,
vortexed every 10 min for 1 h, and centrifuged at 10,000
× g for 20 min at 4°C. The supernatant was then col-
lected as an antigen protein sample and stored at -80°C
until use. The final protein concentration was deter-
mined using a BCA protein assay kit (Thermo Fisher
Scientific, Fremont, CA).
Reverse capture ELISA for Detection of CDC25B
Autoantibodies
A 96-well plate (Costar) was coated overnight with puri-
fied anti-CDC25B monoclonal antibody (100 ng/well in
50 mM bicarbonate buffer (pH 9.0), Cell Signaling Tech-
nology, Danvers, MA) at 4°C. Wells were then blocked
for 2 h at 37°C with 3% bovine serum albumin (BSA) in
PBS. The antigen protein sample was diluted in PBS (pH
7.0) to final concentrations of 20 mg/ml, 10 mg/ml and
5 mg/ml, added to blocked wells (100 μl/well) and incu-
bated overnight at 4°C. Wells were then washed three
times with PBST (0.1% (v/v) Tween 20 in PBS), and the
100 μl serum samples (1:200 dilution with PBST) were
incubated in the wells for 2 h at 37°C. Rabbit anti-human
CDC25B polyclonal antibody (1:10,000 dilution in PBST,
A b c a m )w a su s e da sap o s i t i v ec o n t r o l ,a n d3 %B S A
served as a negative control. After washing the wells four
times with PBST, each well was incubated with a
1:10,000 dilution of 100 μl goat anti-human or anti-rabbit
IgG-HRP conjugate (Santa Cruz Biotechnology, Santa
Cruz, CA) for 1 h at 37°C. The wells were then washed
with PBST and incubated with TMB developing reagent
for 5 min in the dark. The reactions were stopped with
0.5 mol/L H2SO4 and the absorbance of each well was
measured at 450 nm using a Multiskan Spectrum plate
reader (Thermo LabSystems). Sera from ESCC patients
and healthy volunteers were tested simultaneously, and
each sample was assayed twice in duplicate wells.
CEA, SCC and CYFRA21-1 Assay
Serum CEA and CYFRA21-1 were assessed by an elec-
trochemiluminescence immunoassay using E170 analy-
zer (Roche Diagnostics Gmbh, Roche, USA). Serum
SCC-Ag was measured by a microparticle enzyme
immunoassay (ABBOTT Diagnostics, Abbott, USA).
Statistical Analysis
All statistical analyses were performed using the SPSS
16.0 software package. The cut-off value for seropositivity
of CDC25B-Abs was identified by the ROC curve. Pear-
son’s chi-square test or Fisher’s exact test was employed
to assess the association between CDC25B seropositivity
and clinicopathologic characteristics. The statistical dif-
ference in CDC25B-Abs levels between patients with
tumors and healthy control subjects was evaluated using
the Mann-Whitney U test. Survival curves were esti-
mated by Kaplan-Meier plots and log-rank tests. Cox
proportional hazard regression analysis was used to esti-
mate the hazard ratios of independent factors for survi-
val. P < 0.05 in all case was considered statistically
significant.
Results
Anti-CDC25B autoantibodies in sera of patients with ESCC
One hundred thirty-four patients with ESCC were
enrolled in the study (Table 1). The presence of
CDC25B autoantibodies in sera of ESCC patients was
assessed by reverse capture ELISA. The extract of Eca-
109 cells, which presented the highest CDC25B protein
level among the ESCC tumor cell lines tested (Eca-109,
Kyse140, TE-1 and the immortalized cell line NE-3)
(Figure 1A), was used as the source of CDC25B antigen
for reverse capture ELISAs. To determine the optimal
amount of Eca-109 cell extract for use in these assays,
20 sera samples from ESCC patients and 20 sera sam-
ples from healthy controls were evaluated by reverse
capture ELISA. As shown in Figure 1B, 10 μg/well of
total Eca-109 cell protein was determined to be the opti-
mal protein concentration. The within-run coefficient of
variation (CV) for a patient sample (OD 1.35) and a
healthy control sample (OD 0.23) were 10.3% and 9.1%,
respectively, as determined by repeating the assay
20 times. Under these conditions, the average absor-
bance was 0.378 (SD = 0.262) in sera from 134 healthy
control subjects and 0.917 (SD = 0.473) in sera from
134 patients with primary ESCC (Figure 2A). The circu-
lating levels of CDC25B-Abs in patients with ESCC
were significantly higher than those of healthy control
subjects (P < 0.001).
Sensitivity and specificity of serum CDC25B-Abs, CEA, SCC
and CYFRA21-1 in detection of ESCC
T h eR O Cc u r v ew a sp l o t t e dt oi d e n t i f yac u t - o f fv a l u e
that would distinguish ESCC from nonmalignant eso-
phageal diseases. According to the ROC curve, the opti-
mal cut-off value was 0.725, providing a sensitivity of
56.7% and a specificity of 91.0%. The area under the
ROC curve for CDC25B-Abs was 0.870 (95% CI: 0.835-
0.920; Figure 2B). CDC25B-Abs were found in sera from
76 of 134 (56.7%) patients with ESCC, but in sera from
only 11 of 134 (8.2%) healthy controls. Serum CDC25B-
Abs were detected in a higher proportion of patients
with ESCC than healthy control subjects (P < 0.001,
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patients contained SCC-Ag at levels above the cut-off
value of 1.5 ng/ml, 13.4% of ESCC patients contained
CEA at levels above the cut-off value of 5.0 ng/ml and
32.1% of ESCC patients with the sera CYFRA21-1 levels
above the cut-off value of 3.5 ng/ml. (Table 2). These
data indicate that the percentage of CDC25B-Abs sero-
positivity in patients with ESCC is dramatically higher
the percentages of seropositivity of the previously
described tumor markers SCC-Ag, CEA and CYFRA21-
1 in these patients. In addition, sera from 41.0% of
patients with ESCC were positive for CEA, SCC-Ag or
CYFRA21-1, while sera from 64.2% of patients with
ESCC were positive for CEA, SCC-Ag, CYFRA21-1 or
CDC25B-Abs (Table 2). The sensitivity of these four
markers used in combination was slightly higher than
that of the CDC25B-Abs marker alone but significantly
higher than that of CEA, SCC-Ag and CYFRA21-1 used
in combination (P < 0.001).
Association between CDC25B-Abs and Clinicopathological
Characteristics
The data presented in Table 1 show the relationship
between CDC25B-Abs and clinicopathological variables
in ESCC. CDC25B-Abs were not obviously correlated
with T classification, N classification or metastasis; how-
ever, there was a significant association between the pre-
sence of CDC25B-Abs and ESCC clinical stage (P =
0.002). The percentage of CDC25B-Abs seropositivity
was higher in patients with advanced disease than in
patients with early disease.
Table 1 Association between the clinical pathologic features of ESCC and the presence of CDC25B-Abs
CDC25B-Abs
Characteristics Total (n = 134) OD(SD) Positive cases n (%) Negative cases n (%) P
Gender
Male 93 0.913(0.496) 48 (51.6) 45 (48.4) 0.053
Female 41 0.921(0.431) 28 (68.3) 13 (31.7)
Age (y)
<60 73 0.871(0.491) 44 (60.3) 29 (47.5) 0.231
≥60 61 0.968(0.458) 32(52.5) 29 (39.7)
Stage
I-II 80 0.892(0.478) 37 (46.3) 43 (53.7) 0.002
III-IV 54 0.958(0.481) 39 (72.2) 15 (27.8)
pT classification
T1-T2 48 0.904(0.482) 28 (58.3) 20 (41.7) 0.461
T3-T4 86 0.919(0.477) 48 (55.8) 38 (44.2)
pN classification
YES 53 0.980(0.511) 29 (54.7) 24 (45.3) 0.420
NO 81 0.873(0.451) 47 (58.0) 34 (42.0)
Metastasis
YES 8 0.917(0.436) 3 (37.5) 5 (62.5) 0.222
NO 126 0.932(0.484) 73 (57.9) 53 (42.1)
OD: optical density
Figure 1 Expression of CDC25B in different ESCC cell lines and
optimization of antigen concentration for ELISA assays.A .
Expression of CDC25B in ESCC cell lines was examined by Western
blot analysis with an anti-CDC25B antibody (N: normal esophageal
tissue). B. Effect of different amounts of Eca-109 total protein on
absorbance at 450 nm in CDC25B-Abs reverse capture ELISA.
Twenty samples from patients with ESCC and twenty samples from
healthy controls were tested in reverse capture ELISAs using
different amounts of Eca-109 total protein as antigen. The results
shown are the mean values of three experiments.
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The overall survival of ESCC patients was plotted using
the Kaplan-Meier method, and a log-rank test was
employed to evaluate the prognostic significance of
CDC25B-Abs. There was no statistical difference
between the survival rate of the CDC25B-seronegative
patients and that of the CDC25B-seropositive patients
(P = 0.992) (Figure 3A). We then analyzed the potential
prognostic value of CDC25B-Abs in different subgroups
of patients stratified according to the clinical stage of
the patient’s tumor, T classification and N classification.
As shown in Figure 3, for the subgroup with clinical
stage III-IV tumors, the cumulative five-year survival
rate was 43.4% in the CDC25B-seronegative patients
and 6.7% in the CDC25B-seropositive patients (P =
0.001, log-rank). In a similar analysis of the N1 sub-
group, the cumulative five-year survival rate was 54.5%
Figure 2 CDC25B autoantibodies in sera from patients with
ESCC and healthy controls and ROC Curve analysis. A. CDC25B-
Abs were detected by reverse capture ELISA in sera from patients
with ESCC (Patient) and healthy controls (Control). The horizontal
line indicates the cut-off value used to define positive samples. The
results shown are the mean values of two independent
experiments. B. ROC curve of CDC25B-Abs in sera from patients with
ESCC. The area under the ROC curve is 0.870. The cut-off value is
determined according to the ROC curve.
Table 2 The sensitivity of CDC25B-Abs, CEA, CYFRA21-1
and SCC-Ag in detection ESCC
Tumor Markers Total
n
Positive Negative
n (%) n (%) P
CDC25B-Abs 134 76 (56.7) 58 (43.3)
SCC-Ag 134 23 (17.2) 111 (82.8)
CEA 134 18 (13.4) 116 (86.6)
CYFRA 21-1 134 43 (32.1) 91 (67.9)
CEA, SCC-Ag 134 55 (41.0) 79 (59.0)
or CYFRA21-1
CEA, SCC-Ag, 134 86 (64.2) 48 (35.8) <0.001*
CYFRA21-1 or CDC25B-Abs
Abs: antibodies; CEA: carcinoembryonic antigen; SCC-Ag: squamous cell
carcinoma antigen; CYFRA21-1: cytokeratin 19 fragment antigen 21-1.
*compared with either CEA, SCC-Ag or CYFRA21-1. Cut-off values: 5.0 ng/ml
for CEA; 1.5 ng/ml for SCC-Ag; 3.5 ng/ml for CYFRA21-1
Figure 3 Kaplan-Meier curves with univariate analyses (log-
rank) for patients with positive CDC25B expression versus
negative CDC25B expression. The five-year survival rates of
seropositive (bold line) and seronegative (dotted line) ESCC patients
are not significantly different (A, P = 0.992, log-rank). The survival
rates of CDC25B-seropositive and CDC25B-seronegative patients
were compared in subgroups with stage I-II (B) and stage III-IV ESCC
(C). The same comparison was carried out in patients classified into
the T1-T2 (D), T3-T4 (E), N0 (F) and N1 (G)groups. P values were
calculated using the log-rank test.
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CDC25B-seropositive patients (Figure 3G) (P =0 . 0 4 0 ,
log-rank). In addition, multivariate survival analysis was
used to determine whether circulating CDC25B-Abs
were an independent prognostic factor. Our results
showed that the level of circulating CDC25B-Abs had a
significant relationship with the prognosis of patients
with advanced ESCC (P = 0.001) (Table 3); however, the
difference between CDC25B-seropositive patients and
CDC25B-seronegative patients was not statistically sig-
nificant in patients classified into the stage I-II (P =
0.606, log-rank; Figure 3B), T1-T2 (P = 0.320, log-rank;
Figure 3D), T3-T4 (P = 0.486, log-rank; Figure 3E) and
N0 (P = 0.127, log-rank; Figure 3F) subgroups.
Discussion
The identification of tumor antigens that elicit an
immune response is important for clinical applications;
tumor antigens may used for early diagnosis, prognosis,
and immunotherapy against the disease[29]. In this
study, we show that CDC25B-Abs in sera from ESCC
patients were more sensitive than CEA, SCC-Ag and
CYFRA21-1 for diagnosis of ESCC. Moreover, serum
levels of CDC25B-Abs were correlated with the clinico-
pathologic characteristics present in patients with
advanced ESCC.
CEA, SCC-Ag and CYFRA21-1 have been used as
tumor markers for diagnosis of ESCC [30]. However,
reliance on the three tumor markers for the detection of
ESCC has not been satisfactory, especially because of
the poor sensitivity of these tumor markers for ESCC
[31]. In line with previous studies, our current study
showed that the sensitivity of CEA, SCC-Ag or
CYFRA21-1 for detection of ESCC was less than 35%
[32-34]. To circumvent the problem of low sensitivity,
we and others have begun to evaluate the use of autoan-
tibodies against tumor antigens to detect ESCC. Ralhan
has shown that anti-p53 antibodies were found in 60%
sera from patients with ESCC[5], and Shimada has
reported that anti-p53 antibodies were found in 40%
sera from patients with ESCC and surveillance of serum
p53-Abs was superior to CEA, SCC-Ag and CYFRA21-1
[6]. Autoantibody against Prx VI was found in sera from
50% of patients with ESCC[11]. Serum anti-myomegalin
antibodies were present in 47% of patients with ESCC
[8]. Our previous study showed that 36.3% of ESCC
patients with autoantibody responses to CDC25B [12].
These results suggest that autoantibodies increase the
sensitivity of detection of ESCC and might be useful
tumor markers for ESCC diagnosis.
In the current study, CDC25B autoantibodies were
detected in sera of ESCC patients by reverse capture
ELISA. This technology is based on capturing specific
antigens from tumor cell lysates with antibodies, allow-
ing the antigens to be immobilized in their native con-
figuration [35-37]. Due to optimization of the reverse
capture ELISA in current study, the sensitivity of this
assay is higher than in our previous report (36.3%), but
its specificity is lower than that reported in our previous
study (100%) [12]. The rate of CDC25B-Abs seropositiv-
ity in patients with ESCC was significantly higher than
the seropositivity rates of tumor markers SCC-Ag, CEA
and CYFRA21-1. Moreover, the combination of
CDC25B-Abs and conventional tumor markers, CEA,
SCC-Ag, and CYFRA21-1 significantly increased the
sensitivity of detection of ESCC. Our data suggest that
CDC25B-Abs could be a potential biomarker for ESCC
diagnosis.
In addition, our results demonstrate that CDC25B
autoantibodies were more prevalent in sera from
patients with advanced ESCC than in sera from patients
with early stage disease (P < 0.001) and that in the
patients with clinical stage III-IV and N1 subgroup,
CDC25B-Abs seronegative patients survived longer than
CDC25B-Abs seropositive patients. This observation
may be explained by the higher incidence of CDC25B
overexpression in advanced ESCC than in early stage
tumors[22,25]. CDC25B protein expression increased as
tumors progressed; none of the healthy control subjects
expressed CDC25B, while one-fourth of the dysplasia
subjects and one-half of the patients with invasive can-
cer expressed CDC25B[25]. Moreover, overexpression of
CDC25B was also more frequently found in patients
with deep tumor invasion and lymph node metastasis
Table 3 Univariate and multivariate analysis of different prognostic parameters in ESCC patients in the N1 subgroup
by Cox regression analysis
Univariate analysis Multivariate analysis
No. patients P Regression coefficient(SE) P Relative risk 95% confidence interval
pT classification
T1-T2 7 0.015 0.405(0.196) 0.040 1.499 1.020-2.202
T3-T4 37
CDC25B-Abs
Seronegative 18 0.001 0.633(0.196) 0.001 1.882 1.283-2.762
Seropositive 26
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expression of CDC25B in advanced ESCC may thus lead
to high production of CDC25B-Abs in patients with
advanced tumors. These results suggest that detection of
serum CDC25B-Abs is a useful non-invasive marker for
identifying advanced ESCC patients with poor prognosis.
In summary, the levels of CDC25B-Abs in sera from
ESCC patients were significantly higher than those in
sera from healthy subjects. Detection of CDC25B-Abs in
combination with CEA, SCC-Ag, CYFRA21-1 results
in significantly increased sensitivity of detection, with
64.2% of ESCC patients testing positive for at least one
of these markers. Moreover, our study has demonstrated
the prognostic significance of serum CDC25B-Abs in
ESCC and the clinical implications of CDC25B-Abs ser-
opositivity on lymph node metastasis and advanced
stage ESCC. High levels of CDC25B autoantibodies in
sera were significantly associated with poor survival in
advanced ESCC. CDC25B autoantibodies are thus a use-
ful prognostic predictor for advanced ESCC.
Conclusions
Our findings indicate that the levels of CDC25B-Abs in
sera from patients with ESCC are significantly higher
than those of other tumor markers. Moreover, high
levels of CDC25B-Abs were associated with poor survi-
val in advanced ESCC. Multivariate survival analysis
showed that CDC25B-Abs are a potential prognostic
serological marker for advanced ESCC. CDC25B-Abs
therefore provide a valuable serological marker in the
prognostic evaluation of advanced ESCC.
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